Skip to Main Content

File this under “What were they thinking?”

Novo Nordisk (NVO) has agreed to pay more than $58 million to settle allegations that it failed to adequately alert doctors one of its diabetes drugs may be associated with thyroid cancer, a step that was required by regulators at the time its medicine was approved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!